{"filing":{"accession_number":"0001437749-26-024037","cik":"0001719406","ticker":"NRXPW","company_name":"NRX Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"nrxp20260722_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1719406/000143774926024037/nrxp20260722_8k.htm"},"events":[{"id":19319,"run_id":17380,"accession_number":"0001437749-26-024037","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"NRX Pharmaceuticals disclosed that its subsidiary NRXD was selected by DARPA for contract negotiation on a clinical trial (SPARC-TMS) combining D-cycloserine with robotic-enabled TMS for depression treatment. This represents a material operational and strategic milestone—selection for negotiation of a potential government research award—that would affect a reasonable investor's assessment of the company's pipeline and commercial prospects, though the filing explicitly notes this is not yet a binding award.","company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXPW","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18380,"accession_number":"0001437749-26-024037","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NRX Pharmaceuticals disclosed that its subsidiary NRXD was selected by DARPA for contract negotiation on a clinical trial (SPARC-TMS) combining D-cycloserine with robotic-enabled TMS for depression treatment. This represents a material operational and strategic milestone—selection for negotiation of a potential government research award—that would affect a reasonable investor's assessment of the company's pipeline and commercial prospects, though the filing explicitly notes this is not yet a binding award.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T11:02:38.726657+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18380,"accession_number":"0001437749-26-024037","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NRX Pharmaceuticals disclosed that its subsidiary NRXD was selected by DARPA for contract negotiation on a clinical trial (SPARC-TMS) combining D-cycloserine with robotic-enabled TMS for depression treatment. This represents a material operational and strategic milestone—selection for negotiation of a potential government research award—that would affect a reasonable investor's assessment of the company's pipeline and commercial prospects, though the filing explicitly notes this is not yet a binding award.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T11:02:38.726657+00:00","company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXPW","filing_date":"2026-07-22"}]}